Literature DB >> 17897294

Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis.

Anne F McGettrick1, Luke A J O'Neill.   

Abstract

Toll-like receptors (TLRs) play a critical role in the induction of the immune response to invading pathogens. The detection of pathogens by TLRs initiates a signalling cascade that results in the activation of transcription factors such as nuclear factor (NF)-kappaB and interferon regulatory factors leading to the production of pro-inflammatory cytokines and type 1 interferons. Five cytoplasmic adaptors, MyD88, Mal, Trif, TRAM and SARM, are utilized by the TLRs to activate these signalling pathways. Through the years the main focus of research has been on the activation and function of TLRs in monocytic cells. This review discusses several additional roles of TLRs. TLR activation plays a role in influencing the differentiation of haematopoietic stem cells. Their activation also prevents apoptosis in neutrophils following pathogen invasion. B cells and T cells proliferation and differentiation is influenced by TLR activation and the possible therapeutic benefits of using TLR ligands for the treatment of chronic lymphocytic leukaemia will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897294     DOI: 10.1111/j.1365-2141.2007.06802.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  35 in total

1.  Innate immune stimuli modulate bone marrow-derived dendritic cell production in vitro by toll-like receptor-dependent and -independent mechanisms.

Authors:  Joan E Downes; Stuart Marshall-Clarke
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

Review 2.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

3.  Social stress enhances IL-1beta and TNF-alpha production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells.

Authors:  Michael T Bailey; Steven G Kinsey; David A Padgett; John F Sheridan; Binnaz Leblebicioglu
Journal:  Physiol Behav       Date:  2009-06-26

4.  MyD88 provides a protective role in long-term radiation-induced lung injury.

Authors:  Willie J Brickey; Isabel P Neuringer; William Walton; Xiaoyang Hua; Ellis Y Wang; Sushmita Jha; Gregory D Sempowski; Xuebin Yang; Suzanne L Kirby; Stephen L Tilley; Jenny P-Y Ting
Journal:  Int J Radiat Biol       Date:  2012-02-06       Impact factor: 2.694

Review 5.  TLR4 Polymorphisms and Expression in Solid Cancers.

Authors:  Nilesh Pandey; Alex Chauhan; Neeraj Jain
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 6.  Innate pathways to B-cell activation and tolerance.

Authors:  Steve P Crampton; Elisaveta Voynova; Silvia Bolland
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

7.  Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4.

Authors:  Maria Velegraki; Helen Koutala; Christos Tsatsanis; Helen A Papadaki
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

8.  Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis.

Authors:  Yu-Zhong Wang; Mei Yan; Fa-Fa Tian; Jun-Mei Zhang; Qun Liu; Huan Yang; Wen-Bin Zhou; Jing Li
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

9.  Generation of eosinophils from unselected bone marrow progenitors: wild-type, TLR- and eosinophil-deficient mice.

Authors:  Kimberly D Dyer; Caroline M Percopo; Helene F Rosenberg
Journal:  Open Immunol J       Date:  2009-01-01

10.  The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells.

Authors:  Lei Li; Feng-Wei Cheng; Fang Wang; Bo Jia; Xin Luo; Sheng-Quan Zhang
Journal:  Mol Cell Biochem       Date:  2013-12-18       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.